Ministry Official for Industry and Commerce of New South Wales Pays Visit to Novotech's Seoul Office to Boost Clinical Trial Partnerships
Headline: Novotech: Bolstering Collaboration Between Australia and South Korea in Clinical Research
Subheadline: A Look into the Deepening Partnership Between Two Nations and Novotech's Role in Fostering Biopharmaceutical Growth
South Korea and Australia are taking their partnership in the field of clinical research to the next level, with Novotech - a globally renowned clinical research organization - serving as a central figure in this alliance.
The Hon. Anoulack Chanthivong, New South Wales Minister for Industry and Trade, recently paid a visit to Novotech's Seoul office, solidifying the mutual commitment to strengthening ties between the two countries in the biopharmaceutical sector.
"Novotech is an exceptional example of NSW's robust life sciences and clinical trials landscape," said Minister Chanthivong. "I was captivated by Novotech's achievements in the Republic of Korea and the integral role they play in bringing Korean biotech innovation to the world. We, at NSW Investment, are excited to continue supporting Novotech as they bolster export dollars for our state and contribute to solving critical health issues globally."
Accompanied by Brooke O'Rourke, Chief of Staff to Minister Chanthivong, Rebecca McPhee, Deputy Secretary of Investment NSW, David Lawson, NSW Trade & Investment Commissioner for Japan & Korea, and Yoojin Kim, NSW Trade & Investment Director for Korea, the delegation held productive discussions with Novotech's leaders, Dr. Yooni Kim, Hyun Kim, and Lilian Kim.
During their meeting, the team delved into Novotech's growth trajectory as a global clinical research organization and the growing significance of South Korea as a premier destination for clinical trials.
"We are thrilled to have the Australian NSW Trade Minister and senior officials from NSW Investment recognize Novotech as a beacon of collaboration between Australia and South Korea," remarked Dr. Yooni Kim, Managing Director - Asia-Pacific at Novotech. "This visit reaffirms the strong and evolving partnership between the two nations in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, we remain dedicated to generating more success stories that highlight the value of this collaboration. I am confident that our partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market."
The talks underscored Novotech's relationships with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increased interest from Korean biotechs to conduct research in Australia, both parties are actively exploring opportunities to enhance bilateral cooperation and speed up cross-border clinical development.
Having been recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, Novotech continually fortifies its standing as the region's preeminent clinical development partner. By offering Korean biotech sponsors access to Australia's top-tier research infrastructure, regulatory know-how, and accelerated clinical pathways through its integrated full-service model, Novotech empowers Korean biotechs to confidently expand early-phase programs into Australia with the backing of deep regional knowledge and globally consistent operational standards.
About Novotech
Founded in Australia, Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a sprawling global footprint encompassing 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with over 5,000 trial sites, Novotech provides clients an expedited path to bring life-changing therapies to market by offering access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that hasten the path to market for groundbreaking therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, fostering innovation, and enhancing healthcare worldwide.
Recognized for its excellence in clinical trial execution and innovation, Novotech is renowned for its deep therapeutic and regulatory expertise, combined with local market insights, ensuring streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Join Novotech in driving innovation and delivering impactful results. For more information or to speak with an expert team member, visit www.Novotech-CRO.com.
** contact**
Media ContactToyna Chin, [email protected], USA: +1 415 364 8135
Author
Business Wire, View all posts
Press release, Business Wire, Send an email.
- The partnership between South Korea and Australia in the clinical research sector is expanding, with a focus on strengthening their biopharmaceutical industry through collaboration with organizations like Novotech.
- Infrastructure for clinical trials is becoming increasingly significant, as both countries seek to capitalize on the growing interest in South Korea as a premier destination for such research.
- The cloud, in terms of data management and analytical tools, plays a crucial role in enabling efficient collaboration between stakeholders in the medical-conditions, health-and-wellness, and science industries across borders.
- As Novotech's global presence continues to grow, particularly within the finance sector, they are well-positioned to facilitate business opportunities for Korean biotech companies seeking to expand early-phase programs into Australia.
